CENTEK(SZ:000931) Zheng Quan Shi Bao Wang·2025-11-14 07:43Core Viewpoint - The management of Zhongguancun has demonstrated strong confidence in the company's future development and long-term investment value through consistent stock purchases since 2015, with no sell-offs over the past decade [1][2]. Group 1: Management Shareholding - The management team, including the chairman and president, has increased their shareholding multiple times since 2015, with the latest increase planned for February 2024, reflecting their commitment to the company [1]. - As of the mid-2025 report, key management members hold significant shares: 190,000 shares by the chairman, 100,000 by the CFO, and smaller amounts by other executives, all without any reductions in their holdings over ten years [1]. Group 2: Business Strategy and Performance - Since 2015, the company has focused on the "pharmaceutical and health industry" as its core strategy, leading to a steady increase in revenue from its pharmaceutical business [2]. - In 2021, the company further concentrated on its pharmaceutical main business, aiming to build an "innovative pharmaceutical industry group," and in July 2024, it refined its strategy to become a leading service provider in the health industry [2]. Group 3: Product Development and Market Position - The company is actively enhancing its product matrix in the controlled substance sector, with recent approval of a generic drug, which is the first of its kind in the domestic market, expected to improve its competitive edge [3]. - The introduction of new products, such as the hydromorphone injection and the development of methylphenidate, alongside the expansion of its light-asset model in the elderly care sector, positions the company for sustainable growth and value creation for investors [3].